OBJECTIVE: Tenofovir disoproxil fumarate is a widely used antiretroviral for HIV infection that has been associated with an increased risk of chronic kidney disease (CKD). Our objective was to derive a scoring system to predict 5-year risk of developing CKD in HIV-infected individuals and to estimate difference in risk associated with tenofovir use. DESIGN: We evaluated time to first occurrence of CKD (estimated glomerular filtration rate <60 ml/min per 1.73 m(2)) in 21 590 HIV-infected men from the Veterans Health Administration initiating antiretroviral therapy from 1997 to 2010. METHODS: We developed a point-based score using multivariable Cox regression models. Median follow-up was 6.3 years, during which 2059 CKD events occurred. RESULTS: Dominant contributors to the CKD risk score were traditional kidney risk factors (age, glucose, SBP, hypertension, triglycerides, proteinuria); CD4(+) cell count was also a component, but not HIV RNA. The overall 5-year event rate was 7.7% in tenofovir users and 3.8% in nonusers [overall adjusted hazard ratio 2.0, 95% confidence interval (CI) 1.8-2.2]. There was a progressive increase in 5-year CKD risk, ranging from less than 1% (zero points) to 16% (≥9 points) in nonusers of tenofovir, and from 1.4 to 21.4% among tenofovir users. The estimated number-needed-to-harm (NNH) for tenofovir use ranged from 108 for those with zero points to 20 for persons with at least nine points. Among tenofovir users with at least 1 year exposure, NNH ranged from 68 (zero points) to five (≥9 points). CONCLUSION: The CKD risk score can be used to predict an HIV-infected individual's absolute risk of developing CKD over 5 years and may facilitate clinical decision-making around tenofovir use.
OBJECTIVE: Tenofovir disoproxil fumarate is a widely used antiretroviral for HIV infection that has been associated with an increased risk of chronic kidney disease (CKD). Our objective was to derive a scoring system to predict 5-year risk of developing CKD in HIV-infected individuals and to estimate difference in risk associated with tenofovir use. DESIGN: We evaluated time to first occurrence of CKD (estimated glomerular filtration rate <60 ml/min per 1.73 m(2)) in 21 590 HIV-infected men from the Veterans Health Administration initiating antiretroviral therapy from 1997 to 2010. METHODS: We developed a point-based score using multivariable Cox regression models. Median follow-up was 6.3 years, during which 2059 CKD events occurred. RESULTS: Dominant contributors to the CKD risk score were traditional kidney risk factors (age, glucose, SBP, hypertension, triglycerides, proteinuria); CD4(+) cell count was also a component, but not HIV RNA. The overall 5-year event rate was 7.7% in tenofovir users and 3.8% in nonusers [overall adjusted hazard ratio 2.0, 95% confidence interval (CI) 1.8-2.2]. There was a progressive increase in 5-year CKD risk, ranging from less than 1% (zero points) to 16% (≥9 points) in nonusers of tenofovir, and from 1.4 to 21.4% among tenofovir users. The estimated number-needed-to-harm (NNH) for tenofovir use ranged from 108 for those with zero points to 20 for persons with at least nine points. Among tenofovir users with at least 1 year exposure, NNH ranged from 68 (zero points) to five (≥9 points). CONCLUSION: The CKD risk score can be used to predict an HIV-infected individual's absolute risk of developing CKD over 5 years and may facilitate clinical decision-making around tenofovir use.
Authors: Rebecca Scherzer; Michelle Estrella; Yongmei Li; Andy I Choi; Steven G Deeks; Carl Grunfeld; Michael G Shlipak Journal: AIDS Date: 2012-04-24 Impact factor: 4.177
Authors: Lynda Anne Szczech; Stephen J Gange; Charles van der Horst; John A Bartlett; Mary Young; Mardge H Cohen; Kathryn Anastos; Preston S Klassen; Laura P Svetkey Journal: Kidney Int Date: 2002-01 Impact factor: 10.612
Authors: Andy Choi; Rebecca Scherzer; Peter Bacchetti; Phyllis C Tien; Michael S Saag; Cynthia L Gibert; Lynda A Szczech; Carl Grunfeld; Michael G Shlipak Journal: Am J Kidney Dis Date: 2010-08-14 Impact factor: 8.860
Authors: Joel E Gallant; Schlomo Staszewski; Anton L Pozniak; Edwin DeJesus; Jamal M A H Suleiman; Michael D Miller; Dion F Coakley; Biao Lu; John J Toole; Andrew K Cheng Journal: JAMA Date: 2004-07-14 Impact factor: 56.272
Authors: Lisa I Backus; Sergey Gavrilov; Timothy P Loomis; James P Halloran; Barbara R Phillips; Pamela S Belperio; Larry A Mole Journal: J Am Med Inform Assoc Date: 2009-08-28 Impact factor: 4.497
Authors: Kathleen Squires; Anton L Pozniak; Gerald Pierone; Corklin R Steinhart; Daniel Berger; Nicholaos C Bellos; Stephen L Becker; Michael Wulfsohn; Michael D Miller; John J Toole; Dion F Coakley; Andrew Cheng Journal: Ann Intern Med Date: 2003-09-02 Impact factor: 25.391
Authors: Andy I Choi; Rudolph A Rodriguez; Peter Bacchetti; Paul A Volberding; Diane Havlir; Daniel Bertenthal; Alan Bostrom; Ann M O'Hare Journal: Clin Infect Dis Date: 2007-12-15 Impact factor: 9.079
Authors: Lene Ryom; Jens D Lundgren; Peter Reiss; Mike Ross; Ole Kirk; Christophe A Fux; Phillipe Morlat; Eric Fontas; Colette Smith; Stephane De Wit; Antonella d'Arminio Monforte; Wafaa El Sadr; Camilla Hatleberg; Andrew Phillips; Caroline Sabin; Matthew Law; Amanda Mocroft Journal: J Infect Dis Date: 2021-02-24 Impact factor: 5.226
Authors: Charles R Swanepoel; Mohamed G Atta; Vivette D D'Agati; Michelle M Estrella; Agnes B Fogo; Saraladevi Naicker; Frank A Post; Nicola Wearne; Cheryl A Winkler; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Christina M Wyatt Journal: Kidney Int Date: 2018-02-03 Impact factor: 10.612
Authors: A Poda; N F Kabore; K Malateste; N De Rekeneire; A Semde; Y Bikinga; A Patassi; H Chenal; E Messou; F Dabis; D K Ekouevi; A Jaquet; A Cournil Journal: HIV Med Date: 2020-11-03 Impact factor: 3.180